Uncategorized

Kailera nets $625M in one of biotech’s biggest-ever IPOs

The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.

​Read More

Published

6 days ago

on

The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.

​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version